World-class neuro-oncology

Our ambition has been to design a neuro-oncology service which treats the whole patient, not just the tumour. The incidence of brain metastasis is increasing, due to better imaging surveillance and improved systemic treatment of extracranial primary disease – up to 30 per cent of cancer patients are likely to develop a brain metastasis. Conventional radiotherapy treatments often lead to cognitive deterioration, with no benefit in terms of survival, but innovative techniques such as stereotactic radiosurgery (SRS) are offering improved quality of life outcomes.

We offer a comprehensive diagnostic service including 3TMRI, PET/CT and genetics and genomic testing and functional MRI (fMRI).

A non–invasive MRI technique, fMRI is used to locate eloquent brain tissue related to speech, vision, movement, etc., to guide neurosurgical planning and tailor surgery for intrinsic brain tumours to avoid neurological deficit and improve patient outcome.

We have now adopted this technique into our neuro-oncology pathway. With the increasing neuro-oncological benefits of surgery for brain tumours, fMRI offers potential further applications to measure brain recovery processes, to optimally stage and monitor treatments. We are the first private service to offer this to our patients in the UK.

In addition, patients are offered a complementary MRI technique called Diffusion tractography imaging. This imaging scan provides additional information about the location of important brain pathways for speech, movement, vision and other behaviours important for patient quality of life.

Our Oxford centre is a centre of excellence for Stereotactic Radiosurgery (SRS) – often described as brain-sparing surgery, SRS has revolutionised the treatment of small tumour sites.

Using a latest-generation linear accelerator, together with ExacTrac, a fast and highly accurate X-Ray system for patient positioning, allows greater precision and reduced treatment times – as little as 20 minutes. Our London centre houses a Gamma Knife for SRS procedures.


We provide a full range of systemic chemotherapies in our private, individual chemotherapy suites. This includes: iQemo management platform; nurses on call 24/7, acute pathways and a dedicated, on-site resident medical officer.

In a world-first partnership with Brainlab and Magic Leap, we have introduced mixed reality to interpret and visualise medical data in 3D format. Mixed reality viewers are used by our doctors to help explain their brain scan, the surgical plans and possible outcomes – offering reassurance to patients and unravelling some of the complexity of treatment in neuro-oncology.

Request a call back

Making a referral is easy. Please request a call back and we will be in contact as soon as possible.
Request a call back
We're treating the patient as a whole, not just their brain tumour Puneet Plaha, Consultant Neuro-oncology Surgeon

Exceptional patient care

Fast referral

New patients referrals to our neuro-oncology service will be seen within 48 hours. Patients ready for radical treatment within five days of scanning and within two days for palliative patients. Same-day scanning, planning and treatment is available on request

Neuro-oncology MDT

Bringing together the expertise of neuro-radiologists and neuroimaging scientists, alongside neuro-oncologists and  neurosurgeons, we can tailor care to and optimise outcomes for each and every patient


Our unique partnership with the Penny Brohn UK charity supports patients to achieve clinically significant improvements in wellbeing.

Patient care

Convenient locations with transport provided for radiotherapy patients, one-to-one cancer nurse specialists, highly skilled radiographers, triage and acute admissions and personalised exercise medicine

Clinical governance

We are CQC inspected and have a comprehensive governance framework that ensures safe treatment protocols, evaluates consultant practising privileges and reviews cases outside standard protocols. Our centre in Oxford is rated ‘Good’ by the Care Quality Commission (CQC).

Case study

A GenesisCare clinical case study for stereotactic radiosurgery

A 46 year old man with a known renal cell carcinoma previously had a good response to immunotherapy. He had a performance status 0-1 and presented with seizures. A CT scan and MRI was performed showing multiple brain metastases.

The case was referred to the GenesisCare Neuro-Oncology MDT with a decision that stereotactic radiosurgery (SRS) was the best option. The patient was successfully treated with SRS to 9 brain metastases in a single visit.

The patient was seen six weeks after treatment, continuing with immunotherapy for his extracranial disease, on low dose steroids and without any focal neurology and performance status 0.

Stereotactic radiosurgeryBrain metastases

Figure 1. 3D computerised reconstruction of brain metastases (9) targeted with SRS

Brain metastases

Figure 2. Transversal, coronal and sagittal views of 3T planning MRI with isodoses covering the metastases and  showing the rapid dose fall off outside of the lesions.

The neuro-oncology team

At GenesisCare in Oxford we have convened a panel of experts with the sole focus of improving outcomes for patients with metastatic disease affecting the brain.

Richard Stacey

Consultant Neurosurgeon, Oxford

Special clinical interest in brain tumours and epilepsy

Luis Aznar-Garcia

Consultant Clinical Oncologist, Nottingham

Neuro-Oncologist specialised in Stereotactic Radiosurgery (brain and spine). SABR oligometastases, HpB and breast cancer.

Pieter Pretorius

Consultant Neuroradiologist, Oxford

Special clinical interest in Diagnostic imaging of conditions of the Central Nervous System, Spine and Head & Neck region including ENT and Orbital conditions.

Fintan Brian John Sheerin

Consultant Neuroradiologist, Oxford

Special clinical interest in diagnostic imaging of conditions of the central nervous system, spine, head and neck region.

Natalie Voets

Neuroimaging scientist, Oxford

Special clinical interest in neuroimaging (MRI, Functional MRI, Tractography).

Meera Nandhabalan

Clinical Oncologist, Oxford

Speciality Neuro-oncology- management of benign and malignant brain tumours, stereotactic radiotherapy

Puneet Plaha

Consultant Neuro-oncology Surgeon, Oxford

Special clinical interest in endoscopic minimally invasive brain tumour surgery and awake surgery.

1 of 7

Partner with us

We are always looking to collaborate with talented consultants.

As an oncologist, surgeon or related cancer specialist, we invite you to partner with us. We welcome requests from individuals and academic institutions to access our state-of-the-art equipment and clinical support for treatment and research. You can also build your knowledge and network with peers at our many CPD events.

Contact your local Referrer Engagement Manager,